{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T16:40:45Z","timestamp":1777394445016,"version":"3.51.4"},"reference-count":20,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2003,12,23]],"date-time":"2003-12-23T00:00:00Z","timestamp":1072137600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2004,2,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>The objectives of this prospective study were to avoid adjuvant treatment for patients with intraocular disease and patients with postlaminar optic nerve invasion (PL\u2010ONI) without full choroidal or scleral invasion. Adjuvant chemotherapy (Regimen 1) was given to patients with scleral invasion, PL\u2010ONI without cut section, and full choroidal and\/or scleral invasion. A more intensive regimen of higher dose intravenous chemotherapy (Regimen 2) and local radiotherapy was given to patients with PL\u2010ONI and compromise at the cut end and to patients with overt extraocular disease.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>Six\u2010month intravenous chemotherapy included carboplatin plus etoposide alternating with cyclophosphamide plus vincristine (Regimen 1) and the same drugs at higher dosage plus idarubicin (Regimen 2). Chemoreduction with carboplatin and vincristine with or without etoposide was given to selected patients (<jats:italic>n<\/jats:italic> = 39 patients).<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>From 1994 to 2001, 169 patients were evaluable at the Hospital Garrahan (Buenos Aires, Argentina). One hundred eighteen patients with intraocular disease had a 5\u2010year disease free survival (DFS) rate of 0.98, including 54 patients with choroidal invasion. None of 22 patients with isolated PL\u2010ONI developed recurrent disease, whereas 2 of 8 patients with concomitant risk factors had tumor recurrences and died. Three of 5 patients with scleral invasion survived, and 7 of 10 patients with cut\u2010end ONI survived. The only patient with metastatic disease that survived (<jats:italic>n<\/jats:italic> = 6) had only lymph node invasion.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>Adjuvant therapy can be avoided in patients with intraocular and isolated PL\u2010ONI. Patients with PL\u2010ONI who also had other risk factors required intensive adjuvant therapy, such as patients with cut\u2010end and overt extraocular disease. Metastatic disease was not found to be curable with this approach. Cancer 2004;100:834\u201342. \u00a9 2003 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.11952","type":"journal-article","created":{"date-parts":[[2004,2,5]],"date-time":"2004-02-05T05:00:32Z","timestamp":1075957232000},"page":"834-842","source":"Crossref","is-referenced-by-count":59,"title":["Results of a prospective study for the treatment of retinoblastoma"],"prefix":"10.1002","volume":"100","author":[{"given":"Guillermo","family":"Chantada","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriana","family":"Fandi\u00f1o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda T. G.","family":"D\u00e1vila","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julio","family":"Manzitti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elsa","family":"Raslawski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Casak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrique","family":"Schvartzman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2004,2,3]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.5.1532"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19960315)77:6<1206::AID-CNCR30>3.0.CO;2-3"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.120.7.923"},{"key":"e_1_2_5_5_2","first-page":"41","article-title":"Evaluation of chemoprophylaxis in patients with unilateral retinoblastoma with high\u2010risk features on histopathologic examination","volume":"119","author":"Uusitalo M","year":"2001","journal-title":"Arch Ophthalmol."},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1076\/opge.20.3.133.2277"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(97)10019-3"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20001115)89:10<2117::AID-CNCR12>3.0.CO;2-9"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/mpo.10249"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11647"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-8588(18)30649-X"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.121.8.1125"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(91)32325-X"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19940201)73:3<692::AID-CNCR2820730331>3.0.CO;2-8"},{"key":"e_1_2_5_15_2","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1200\/JCO.1995.13.4.902","article-title":"Etoposide and carboplatin in extraocular retinoblastoma: a study by the Societ\u00e9 Fran\u00e7aise d'Oncologie P\u00e9diatrique","volume":"13","author":"Doz F","year":"1995","journal-title":"J Clin Oncol."},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-199023000-00008"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.6.1847"},{"key":"e_1_2_5_18_2","first-page":"469","article-title":"Chemosensitivity and multidrug resistance to antineoplastic drugs in retinoblastoma cell lines","volume":"9","author":"Chan HS","year":"1989","journal-title":"Anticancer Res."},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2000.tb07042.x"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-200205000-00011"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/mpo.1358"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.11952","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.11952","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T10:13:57Z","timestamp":1760264037000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.11952"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,2,3]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2004,2,15]]}},"alternative-id":["10.1002\/cncr.11952"],"URL":"https:\/\/doi.org\/10.1002\/cncr.11952","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,2,3]]}}}